TapImmune's CEO Says Company Is Preparing "A Very Deep Pipeline in Multiple Indications" for Phase II Trials Print E-mail
Tuesday, 10 February 2015 12:54
TapImmune Inc. (OTCQB: TPIV), the emerging clinical-stage immunotherapy company which develops peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and infectious diseases has been grabbing the attention of biotech investors as they ready multiple products for Phase II Clinical Trials.
Wednesday, 04 February 2015 10:45
New York, NY--Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that it engaged Dr. Roland Turck, Managing Partner at TurckBio, as a senior advisor to the Board of Directors.
FDA Issues Import Block On Eli Lilly's Cialis; Intrexon, ZIOPHARM, and MD Anderson in Exclusive CAR T Pact Print E-mail
Tuesday, 13 January 2015 20:00
Below is a look at some of the headlines for companies that made news in the healthcare sector on January 13, 2015.
AAA Fully Acquires Atreus Pharmaceuticals; Enrolls First Patient In A Phase I/II Clinical Trial For Its Key Diagnostic Candidate Annexin V-128 In Rheumatoid Arthritis And Ankylosing Spondylitis Print E-mail
Friday, 09 January 2015 08:13
08 January 2015 – Advanced Accelerator Applications S.A. (“AAA” or “the Company”), an international specialist in Molecular Nuclear Medicine (MNM), announced today that it has acquired the remaining 49.9% of Atreus Pharmaceuticals Corporation, a development-stage biopharmaceutical company headquartered in Ottawa, Canada and focused on the development of proprietary molecular imaging products aimed at imaging apoptosis and necrosis based on Annexin V. Atreus Pharmaceuticals Corporation is now a fully owned AAA subsidiary and has been renamed AAA Canada.
Provectus Biopharmaceuticals to Meet with FDA on Operational Aspects of PV-10 Phase 3 Melanoma Study with Aim to Maximize Speed of Enrollment Print E-mail
Tuesday, 23 December 2014 01:02
KNOXVILLE, Tenn.--Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that it will be meeting with the U.S. Food and Drug Administration (the “FDA”) to review certain operational aspects of the protocol for its planned phase 3 clinical trial of intralesional PV-10, its novel investigational drug for cancer, as a treatment for melanoma.
PlasmaTech Biopharmaceuticals, Inc. Announces Pricing of $14,000,000 Public Offering and Listing on NASDAQ Print E-mail
Saturday, 20 December 2014 00:26
DALLAS and NEW YORK--PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI, PTBIW), a biopharmaceutical company advancing patient care in critical areas, announced the pricing of an underwritten public offering of 3,500,000 shares of common stock, and warrants to purchase up to an aggregate 3,500,000 shares of common stock, at an offering price of $4.00 per share and $.01 per warrant.  
The Bakken Invitation Announces 2014 Honorees: 10 Inspiring People Who Live On and Give On Print E-mail
Monday, 08 December 2014 11:18
MINNEAPOLIS--Medtronic (NYSE: MDT) today announced the names of 10 people from around the world who will be honored as part of the Bakken Invitation, a global program launched in 2013 that celebrates and connects people who, with the help of medical technology, have overcome health challenges and are now making a difference in their communities.
Pluristem and Hadassah Medical Center Will Collaborate to Study Potential of PLX-RAD Cells to Improve Bone Marrow and Umbilical Cord Blood Transplant Outcomes Print E-mail
Thursday, 04 December 2014 22:17
HAIFA, ISRAEL--Pluristem Therapeutics Inc. (NasdaqCM: PSTI; TASE: PSTI), a leading developer of placenta-based cell therapy products, announced today that it has entered into a long-term collaboration agreement with Hadassah Medical Center in Jerusalem.
CEL-SCI Quarterly Patient Enrollment in Its Head and Neck Cancer Phase III Trial Increases Eight Fold Over Same Prior Year Period Print E-mail
Tuesday, 02 December 2014 18:51
Vienna, VA--CEL-SCI Corporation (NYSE MKT: CVM) today announced  that during the past three months it has enrolled 58 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). 
Actinium Receives Orphan-Drug Designation from FDA for Actimab-A in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients Print E-mail
Monday, 01 December 2014 18:45
NEW YORK, NY--Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the US Food and Drug Administration (FDA) has granted orphan-drug designation for Actimab-A, an alpha radiolabeled antibody being developed for newly diagnosed AML in patients over the age of 60. Actimab-A is currently in a multicenter Phase 1/2 trial clinical trial.
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 6 of 12